Jesus Berdeja
SCRI Development Innovations, LLC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jesus Berdeja as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02843074 · Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsSCRI Development Innovations, LLC · completed · Multiple Myeloma · study chair
- Ph1NCT01684150 · A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingEpizyme, Inc. · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT01496118 · Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaSCRI Development Innovations, LLC · completed · Multiple Myeloma · study chair
- Ph2NCT01056276 · Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapySCRI Development Innovations, LLC · completed · Multiple Myeloma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- 1,575 citationsRCR 84.7
- 1,433 citationsRCR 50.4
- 715 citationsRCR 23.2
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 2023686 citationsRCR 61.1
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med · 2022670 citationsRCR 46.2
- 388 citationsRCR 11.6
- 228 citationsRCR 6.4
- 177 citationsRCR 5.7
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.Lancet Oncol · 2016172 citationsRCR 5.3